OTCQX:MRVFF - Post by User
Post by
ronzon Jun 04, 2007 8:32pm
367 Views
Post# 12890175
comparitively speaking........
comparitively speaking........I couldn't help but notice that recently another well known (canadian)bio-tech company looking for their approval from the FDA recently took a hit similar to our Nuvo Research when they recieved a second approval letter. This company is Labopharm Inc. (T.DDS), and their product is tramadol. Their president and CEO was quoted as saying that "We are extremely disappointed by the FDA's assessment of our response to its initial approvable letter." Does any of this sound familiar.......!!!!!!!! and yet they have only lost half of their value????? We have been punished much, much, more than them for almost the exact same storyline! Something smells funny here, Labopharm is also a one hit wonder like Nuvo is and somehow we got punished so much more! Has anybody got any thoughts on this?????